DKK 219.60
+1.00 (+0.46%)
DKK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALK-B.CO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
59 interventional · 8 observational · 22 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65NCT07060885Average daily total combined rhinitis score (TCRS) during the primary efficacy assessment period.Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: HDM SLIT-tablet (12 SQ-HDM) · Other: Placebo | Allergic Rhinoconjunctivitis, Allergic Rhinitis | 327 | 2026-09-06 | in 18 d | 2026-07-20 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut AllergyNCT05440643Part 1 and 2: Dose tolerability response rateRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Biological: Peanut SLIT-tablet · Other: Placebo | Peanut Allergy | 209 | 2026-03-10actual | — | 2026-05-11 |
| Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic RhinitisNCT06151938observationalCorrelation between three measurement instruments | — | Unknown status | Drug: Standardised allergen extract from house dust mites | Allergic Rhinitis Due to House Dust Mite, Allergic Asthma | 100 | 2025-05-20 | — | 2024-03-20 |
| Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and AsthmaNCT05476484observationalSymptom-relieving medication use for allergic rhinitis | — | Completed | Drug: SQ SLIT-tablet | Allergic Rhinitis, Asthma, Allergy | 46,196 | 2024-06-30actual | — | 2026-07-20 |
| Observational Study of Allergic Rhinitis in ChildrenNCT05655858observationalProportion of children over 2 years of age with allergic rhinitis eligible for allergic immunotherapy | — | Completed | Other: Management of allergic rhinitis | Allergic Rhinitis | 1,004 | 2024-03-03actual | — | 2025-10-03 |
| A Study in Adults With Grass Pollen-induced RhinoconjunctivitisNCT04881461results2024-12-16Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: 5-grass mix SLIT-drops, Placebo | Allergy | 445 | 2023-09-26actual | — | 2024-12-16 |
| A Study in Children and Adolescents With Birch Pollen-induced RhinoconjunctivitisNCT04878354results2025-01-22Average Total Combined Score (TCS) During the Birch Pollen Season (BPS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tree SLIT-tablet, Placebo SLIT-tablet | Allergy | 952 | 2023-07-31actual | — | 2025-01-22 |
| The Effect of Allergic Rhinitis on Educational OutcomesNCT05881577observationalPrimary school final examination test grades (oral and written) in: Language (Danish, English), Mathematics Obtained high school degree Obtained university degree | — | Unknown status | Other: Observational | Allergic Rhinitis | 150,000 | 2023-07-31 | — | 2023-05-31 |
| House Dust Mite Allergy Trial In ChildrenNCT04145219results2024-06-12Average Daily Total Combined Rhinitis Symptom and Medication Score (TCRS) During the Primary Efficacy Assessment PeriodRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Sublingual allergy immunotherapy tablet · Other: Placebo | Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite | 1,460 | 2023-04-01actual | — | 2024-06-12 |
| Mite Asthma Pediatric Immunotherapy TrialNCT03654976results2023-10-19Annualized Rate of Clinically Relevant Asthma ExacerbationsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: HDM SLIT-tablet · Other: Placebo | Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite | 533 | 2022-05-18actual | — | 2023-10-19 |
| Adolescent Mite Allergy Safety EvaluationNCT04541004results2023-07-03Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: HDM SLIT-tablet | Allergic Rhinitis, Allergic Rhinoconjunctivitis | 253 | 2021-04-24actual | — | 2023-07-03 |
| Impact of AIT on Allergic Rhinitis and AsthmaNCT04125888observationalAllergic rhinitis medication use | — | Completed | Drug: Allergy immunotherapy (AIT) | Allergy, Respiratory Disease | 92,048 | 2021-04-16actual | — | 2021-06-02 |
| N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in FranceNCT03746860observationalSafety analysis: Number of patients with at least one Adverse Event | — | Completed | Drug: Tablet, Dispersible | Allergic Rhinitis Due to House Dust Mite, Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus | 1,508 | 2020-09-29actual | — | 2021-05-17 |
| A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure ChamberNCT04176185Total Nasal Symptom Score (TNSS)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: COVID-19 | Biological: Sublingual allergy immunological tablet · Other: Placebo | Allergic Rhinoconjunctivitis | 80 | 2019-12-17actual | — | 2022-06-30 |
| A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure ChamberNCT02481856Average total rhinoconjunctivitis symptom scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: SQ tree SLIT-tablet, Placebo | Allergic Rhinoconjunctivitis | 219 | Apr 2016actual | — | 2017-01-19 |
| Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral LyophilisateNCT01854736Cellular populations (neutrophils, eosinophils, basophils, monocytes, DCs and lymphocytes populations)Randomized · Quadruple-masked · Basic science | Phase 4 | Completed | Drug: Grazax · Other: Placebo | Allergic Rhinitis Due to Grass Pollens | 51 | Dec 2015actual | — | 2017-06-28 |
| Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge ChamberNCT02166268Average total nasal symptom scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AVANZ Phleum pratense 15,000 SQ+, Placebo | Grass Pollen Induced Allergic Rhinoconjunctivitis | 140 | Oct 2015actual | — | 2016-01-26 |
| Grazax Asthma PreventionNCT01061203Evaluation of allergy and asthma symptomsRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: Grazax, Placebo | Allergic Rhinitis | 812 | Sep 2015actual | — | 2016-09-08 |
| Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)NCT01700192results2017-03-03Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of TreatmentRandomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: MK-8237 tablets, Placebo tablets · Drug: Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets, Rescue Medication: Olopatadine ophthalmic drops, Rescue Medication: Mometasone furoate nasal spray | Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal | 1,482 | Apr 2015actual | — | 2017-09-15 |
| Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)NCT02256553results2016-01-18Percentage of Participants Who Experienced at Least One Event of Local SwellingOpen-label · Treatment | Phase 4 | Completed | Biological: MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract) · Drug: Rescue Medication | Rhinitis, Allergic, Seasonal | 102 | Feb 2015actual | — | 2017-03-03 |
| Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®NCT02437786Changes in immunological markers (composite) measured in grass allergic subjects during treatment with Grazax®Open-label · Other | Phase 4 | Completed | Drug: GRAZAX | Allergic Rhinoconjunctivitis | 58 | Dec 2014actual | — | 2018-01-17 |
| An Open Trial to Assess the Tolerability of AVANZ® Cupressus ImmunotherapyNCT02069535Frequency of patients with IMP-related AEsOpen-label · Treatment | Phase 2 | Completed | Biological: AVANZ Cupressus | Allergic Rhinoconjunctivitis | 52 | Nov 2014actual | — | 2015-01-06 |
| An Open Trial to Assess the Tolerability of AVANZ® Salsola ImmunotherapyNCT02065856Frequency of patients with adverse reactionsOpen-label | Phase 2 | Completed | Biological: AVANZ Salsola | Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen | 51 | Aug 2014actual | — | 2015-01-14 |
| A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)NCT01644617results2017-02-13Average Total Nasal Symptom Score (TNSS) During Environmental Exposure Chamber (EEC) Challenge Session at Week 24Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Placebo, MK-8237 6 DU, MK-8237 12 DU | Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal | 124 | Aug 2013actual | — | 2017-09-15 |
| A Dose Response Evaluation of SLITone Ultra HDM Mix ImmunotherapyNCT01728298Change from baseline in IgE-blocking factor after 6 months of treatmentRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: SLITone ULTRA HDM immunotherapy | Allergic Rhinitis | 219 | Aug 2013actual | — | 2014-01-22 |
| A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy TabletNCT01675791Allergy symptom severity scores on a scale from 0-3Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: ALK tree AIT 0.5 DU, ALK tree AIT 1 DU, ALK tree AIT 2 DU, ALK tree AIT 4 DU, ALK tree AIT 7 DU, ALK tree AIT 12 DU, ALK tree AIT Placebo | Birch Pollen Allergy | 637 | Jul 2013actual | — | 2014-01-22 |
| Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)NCT01678807results2017-02-13Percentage of Participants Who Experienced At Least One Adverse Event (AE)Randomized · Double-masked · Treatment | Phase 1 | Completed | Biological: MK-8237 6 DU, MK-8237 12 DU, Placebo | Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal | 195 | May 2013actual | — | 2017-09-15 |
| House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of AsthmaNCT01433523Time to first moderate or severe asthma exacerbation after ICS reductionRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ALK HDM AIT Placebo, ALK HDM AIT 6 DU, ALK HDM AIT 12 DU | Asthma | 834 | Apr 2013actual | — | 2017-01-30 |
| A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy TabletNCT01454544Evaluation of allergy symptoms and use of symptomatic medicationRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: AIT Tablet | House Dust Mite Allergy | 992 | Apr 2013actual | — | 2017-01-30 |
| An Open Trial to Assess the Tolerability of AVANZ Olive ImmunotherapyNCT01674595Frequency of patients with adverse reactions.Open-label · Treatment | Phase 2/3 | Completed | Biological: AVANZ olea | Allergic Rhinitis Due to Olea Europaea Pollen | 93 | Apr 2013actual | — | 2013-04-30 |
| Avanz Phleum Pratense Maintenance DoseNCT01438827Recording of rhinoconjunctivitis symptomsRandomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: Avanz Phleum pratense, Placebo | Allergic Rhinoconjunctivitis | 450 | Dec 2012actual | — | 2014-01-22 |
| A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)NCT01385371results2013-09-10Average Total Combined Rhinoconjunctivitis Daily Symptom Score (DSS) and Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire Grass Pollen Season (GPS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Grass (Phleum pratense) pollen allergen extract, Placebo for SCH 697243 | Rhinitis Allergic, Conjunctivitis | 1,501 | Aug 2012actual | — | 2017-03-03 |
| An Open Trial to Assess the Tolerability of AVANZ Mite Mix ImmunotherapyNCT01568190Frequency of patients with adverse reactions.Open-label · Treatment | Phase 2/3 | Completed | Biological: AVANZ MITE | Allergic Rhinitis Due to Dust Mite | 102 | Jul 2012actual | — | 2015-01-06 |
| A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)NCT01535118results2014-01-27observationalPercentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC) | — | Completed | — | Allergic Rhinoconjunctivitis | 2,765 | May 2012actual | — | 2017-03-03 |
| Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)NCT01549340results2014-03-06observationalPercentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops | — | Completed | — | Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis | 8,790 | May 2012actual | — | 2017-03-03 |
| A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)NCT01469182results2014-06-05Number of Participants With Treatment-emergent Adverse Events (AEs)Randomized · Double-masked · Treatment | Phase 3 | Completed | Biological: SCH 39641 · Drug: Placebo for SCH 39641 | Allergy | 914 | Apr 2012actual | — | 2017-03-03 |
| An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense ImmunotherapyNCT01454531results2015-03-06Frequency of Subjects With Adverse Drug ReactionsOpen-label · Treatment | Phase 2/3 | Completed | Drug: AVANZ Phleum pratense | Allergic Rhinoconjunctivitis | 199 | Mar 2012actual | — | 2015-03-06 |
| Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced RhinitisNCT01603056results2016-04-29The Change From Baseline in Rhinoconjunctivitis Symptoms Score at 11 - 12 Months Between the Actively Treated Patients and the Placebo Treated.Randomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: Pangramin SLIT HDM mix., Placebo | Allergic Rhinitis | 617 | Feb 2012actual | — | 2016-04-29 |
| Comparison of Different Up-dosing Schedules With Osiris Phleum PratenseNCT01425788Tolerability based on reporting of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Osiris Phleum pratense, Osiris Phleum pratense, Osiris Phleum pratense | Rhino-conjunctivitis | 236 | Nov 2011actual | — | 2015-06-26 |
| Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)NCT00770315results2014-07-03Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Biological: Ambrosia artemisiifolia allergen extract (Amb a 1-U), Placebo | Rhinitis, Allergic, Conjunctivitis | 784 | May 2011actual | — | 2017-03-03 |
| Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)NCT00783198results2014-07-14Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Biological: SCH 39641 6 Amb a 1-U, SCH 39641 12 Amb a 1-U, Placebo | Rhinitis; Allergic, With Asthma, Conjunctivitis | 565 | May 2011actual | — | 2017-03-03 |
| Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS BirchNCT01191359Pharmacodynamic efficacy of two different administration routes of SLITonePLUS BirchRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: oral immunotherapy | Allergy | 66 | Jan 2011actual | — | 2013-02-08 |
| Tolerability of Grazax in Patients With Hayfever in Real Life SettingsNCT01433510Adverse Events related to GrazaxOpen-label · Treatment | Phase 4 | Completed | Drug: Grazax | Allergic Rhinoconjunctivitis | 628 | Oct 2010actual | — | 2024-05-29 |
| Exposure Chamber Trial With Cat ImmunotherapyNCT00987909Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Specific allergen immunotherapy (placebo), Specific allergen immunotherapy, Specific allergen immunotherapy, Specific allergen immunotherapy | Cat Allergy | 60 | Mar 2010actual | — | 2010-08-18 |
| Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)NCT00978029results2014-05-23The Proportion of Participants Reporting Treatment-emergent Adverse Events (AEs)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo · Biological: SCH 39641, SCH 39641 | Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy | 203 | Feb 2010actual | — | 2017-03-03 |
| A Trial of the ALK Grass Tablet in Subjects With HayfeverNCT00227279Recording of rhinoconjunctivitis symptomsRandomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: ALK Grass tablet | Allergy | 634 | Sep 2009actual | — | 2013-01-29 |
| Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)NCT00550550results2012-09-07Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Loratadine Syrup 1 mg/mL Rescue Treatment, Loratadine 10 mg Rescue Treatment, Olopatadine 0.1% Rescue Treatment, Mometasone furoate 50 mcg Rescue Treatment, Albuterol 108 mcg Rescue Treatment, Fluticasone 44 mcg Rescue Treatment, Prednisone 5 mg Rescue Treatment · Biological: SCH 697243 | Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy | 345 | Sep 2009actual | — | 2017-03-03 |
| Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)NCT00562159results2012-09-07Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Loratadine 10 mg Rescue Treatment, Olopatadine 0.1% Rescue Treatment, Mometasone 50 mcg Rescue Treatment, Prednisone 5 mg Rescue Treatment, Albuterol sulfate 108 mcg, Fluticasone propionate 44 mcg, Prednisone 5 mg · Biological: SCH 697243 | Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy | 439 | Sep 2009actual | — | 2017-03-03 |
| Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic PatientsNCT00857779IgE-blocking factorRandomized · Open-label · Treatment | Phase 2 | Completed | Biological: subcutaneous immunotherapy | Rhinitis, Conjunctivitis, Asthma | 473 | Aug 2009actual | — | 2013-02-08 |
| Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen RhinoconjunctivitisNCT01728285To evaluate if compliance with grass Allergy Immunotherapy Tablet can be increased by providing an electronic compliance device (CED) (Memozax; a tablet-container with a programmable daily acoustic alarm)Randomized · Open-label · Treatment | Phase 3 | Completed | Device: Electronic compliance device (Memozax®) | Allergic Rhinitis, Grass Allergy | 261 | Jun 2009actual | — | 2012-11-19 |
| Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic DermatitisNCT00310492Changes from baseline in SCORAD and topical medication consumptionRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: subcutaneous immunotherapy | Atopic Dermatitis | 154 | May 2009actual | — | 2015-12-29 |
| A Trial Evaluating Tolerability of Grazax Treatment in Combination With AntihistamineNCT01740284To evaluate whether intake of antihistamine in connection with Grazax treatment results in a reduction in number of subjects reporting treatment related AEs the first day of Grazax exposureRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Grazax + Aerius, Grazax + placebo | Allergic Rhinoconjunctivitis | 46 | Jan 2009actual | — | 2013-02-08 |
| Efficacy of SLITone in House Dust Mite Allergic PatientsNCT00633919results2011-02-21Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008Randomized · Triple-masked · Treatment | Phase 2/3 | Completed | Biological: SLITone(TM) Dermatophagoides mix, Placebo · Drug: Salbutamol inhaler, Budesonide/formoterol inhaler, Prednisone tablet, Desloratadine tablet, Budesonide nasal spray | Allergy | 124 | Dec 2008actual | — | 2011-06-08 |
| A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax TreatmentNCT00773240Pharmacodynamics - Immunological assessmentsRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Grazax, placebo | Grass Pollen Allergy | 276 | Oct 2008actual | — | 2011-08-30 |
| Intraseasonal Short-time Up-dosing With Alutard SQ GrassesNCT00807547Changes from baseline in Immuno globuline E (IgE)-blocking factorRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Allergy vaccination (Alutard SQ) | Allergy | 149 | Oct 2008actual | — | 2015-12-29 |
| Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced AsthmaNCT00492076Reduction in inhaled corticosteroidsRandomized · Double-masked · Prevention | Phase 4 | Completed | Biological: Pangramin Plus D. pteronyssinus 100% | Allergic Asthma | 45 | May 2008actual | — | 2008-10-16 |
| Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic SubjectsNCT00389363Use of inhaled corticosteroid (ICS).Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: ALK HDM tablet | Asthma | 800 | Apr 2008actual | — | 2010-08-17 |
| Tolerability of ALK Tree TabletNCT00535639Randomized · Double-masked | Phase 1 | Completed | Drug: Betula Verrucosa allergen extract | Allergy | — | Dec 2007actual | — | 2008-02-29 |
| Efficacy and Safety of Grazax in ChildrenNCT00408616Hayfever symptomsRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Grazax-R, Grazax Placebo | Allergy | 253 | Sep 2007actual | — | 2009-03-09 |
| Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass TabletsNCT00413556Difference in serum leves of IgG4Randomized · Triple-masked · Treatment | Phase 3 | Completed | Biological: ALK Grass tablet | Allergy | 76 | Aug 2007actual | — | 2008-03-06 |
| A Trial of Grazax in Subjects With HayfeverNCT00421655Recording of allergy symptomsRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Grazax | Allergy | 329 | Aug 2007actual | — | 2015-06-24 |
| Assessment of Grazax® Treatment ComplianceNCT00293046Assessment of treatment compliance by recording of drug accountabilityRandomized · Open-label | Phase 3 | Completed | Biological: ALK Grass tablet - use of compliance device | Allergy | 500 | Sep 2006actual | — | 2008-09-30 |
| Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With HayfeverNCT00310466results2009-08-06Daily Rhinoconjunctivitis Symptom ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Sublingual immunotherapy, Placebo | Allergy | 226 | Aug 2006actual | — | 2013-05-14 |
| Tolerability of Grazax-R in ChildrenNCT00298701Assessment of safety by recording of adverse eventsRandomized · Double-masked | Phase 1 | Completed | Biological: ALK Grass tablet | Allergy | 50 | — | — | 2006-05-04 |
| Tolerability of ALK Grass Tablet in ChildrenNCT00310453Assessment of safety by recording of adverse eventsRandomized · Double-masked | Phase 1 | Completed | Biological: ALK Grass tablet | Allergy | 32 | — | — | 2006-05-04 |
| Safety of ALK Ragweed TabletNCT00330083Assessment of safety by recording of adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Biological: ALK Ragweed Tablet | Allergy | 72 | — | — | 2007-09-21 |
| Comparison of Different Up-dosing Schedules With OsirisNCT01240954evaluate the tolerability of different up-dosing schedulesRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: CA approval not obtained | Drug: OSIRIS, OSIRIS other concentration 1, OSIRIS other concentration 2 | Allergic Rhinitis | 210 | — | — | 2011-08-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19